Cargando…

BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer

Germline mutations in the BRCA1 or BRCA2 genes are associated with an increased risk of breast and ovarian cancer development. Both genes are involved in DNA repair, and tumors harboring genetic defects in them are thought to be more sensitive to DNA-damaging agents used in chemotherapy. However, as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stefansson, Olafur A., Villanueva, Alberto, Vidal, August, Martí, Lola, Esteller, Manel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2012
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3499323/ https://www.ncbi.nlm.nih.gov/pubmed/23069641 http://dx.doi.org/10.4161/epi.22561

Ejemplares similares

BRCA1 as a tumor suppressor linked to the regulation of epigenetic states: keeping oncomiRs under control
por: Stefansson, Olafur Andri, et al.
Publicado: (2012)

EZH2-mediated epigenetic repression of DNA repair in promoting breast tumor initiating cells
por: Stefansson, Olafur Andri, et al.
Publicado: (2011)

Epigenetic loss of the PIWI/piRNA machinery in human testicular tumorigenesis
por: Ferreira, Humberto J, et al.
Publicado: (2014)

CARM1 and BAF155: an example of how chromatin remodeling factors can be relocalized and contribute to cancer
por: Stefansson, Olafur A, et al.
Publicado: (2014)

Immunotherapy May Improve Tumor Sensitivity to Palliative Chemotherapy in Platinum Resistant Ovarian Cancer
por: Kinney, Rachel E, et al.
Publicado: (2023)

Epigenetic Inactivation of the BRCA1 Interactor SRBC and Resistance to Oxaliplatin in Colorectal Cancer
por: Moutinho, Catia, et al.
Publicado: (2013)

Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs
por: Nogales, Vanesa, et al.
Publicado: (2015)

Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer
por: Birgisdottir, Valgerdur, et al.
Publicado: (2006)

CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer
por: Stefansson, Olafur Andri, et al.
Publicado: (2011)

Epigenetic inactivation of tumour suppressor coding and non-coding genes in human cancer: an update
por: Llinàs-Arias, Pere, et al.
Publicado: (2017)

Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer
por: Della Pepa, Chiara, et al.
Publicado: (2014)

Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer [Corrigendum]
Publicado: (2014)

Epigenetic disruption of cadherin-11 in human cancer metastasis
por: Carmona, F Javier, et al.
Publicado: (2012)

Epigenetic changes in cancer
por: Esteller, Manel
Publicado: (2011)

BRCA testing, treatment patterns and survival in platinum-sensitive recurrent ovarian cancer – an observational cohort study
por: Unni, Sudhir K., et al.
Publicado: (2016)

BECN1 and BRCA1 Deficiency Sensitizes Ovarian Cancer to Platinum Therapy and Confers Better Prognosis
por: Salwa, Amreen, et al.
Publicado: (2021)

New perspective on maintenance therapies for platinum- sensitive recurrent ovarian cancer in women with germline and somatic mutations in BRCA1 and BRCA2 genes
por: Vergote, I, et al.
Publicado: (2016)

ADAMTS16 mutations sensitize ovarian cancer cells to platinum-based chemotherapy
por: Yasukawa, Maya, et al.
Publicado: (2016)

Epigenetic drugs: More than meets the eye
por: Esteller, Manel
Publicado: (2017)

Frequent loss of endothelin-3 (EDN3) expression due to epigenetic inactivation in human breast cancer
por: Wiesmann, Frank, et al.
Publicado: (2009)

BRCA1 Promoter Methylation Status in 1031 Primary Breast Cancers Predicts Favorable Outcomes Following Chemotherapy
por: Stefansson, Olafur A, et al.
Publicado: (2019)

Beyond BRCA Status: Clinical Biomarkers May Predict Therapeutic Effects of Olaparib in Platinum-Sensitive Ovarian Cancer Recurrence
por: Nakanishi, Kazuho, et al.
Publicado: (2021)

Weekly platinum chemotherapy for recurrent ovarian cancer
por: Clamp, A, et al.
Publicado: (2002)

Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma
por: Grande, Enrique, et al.
Publicado: (2023)

TGFβ Controls Ovarian Cancer Cell Proliferation
por: Alsina-Sanchís, Elisenda, et al.
Publicado: (2017)

BRCA1/2 Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum Agents
por: Darabi, Sourat, et al.
Publicado: (2022)

Hot topics in epigenetic mechanisms of aging: 2011
por: Berdasco, María, et al.
Publicado: (2012)

Significance of platinum distribution to predict platinum resistance in ovarian cancer after platinum treatment in neoadjuvant chemotherapy
por: Uno, Kaname, et al.
Publicado: (2022)

Effect of the Combination of Trabectedin and Pegylated Liposomal Doxorubicin in a BRCA2 Mutation Carrier with Recurrent Platinum-Sensitive Ovarian Cancer
por: Rubio Pérez, María Jesús
Publicado: (2017)

DNA methylation profiling in breast cancer discordant identical twins identifies DOK7 as novel epigenetic biomarker
por: Heyn, Holger, et al.
Publicado: (2013)

Platinum-Based Neoadjuvant Chemotherapy for Breast Cancer With BRCA Mutations: A Meta-Analysis
por: Wang, Chang-Jun, et al.
Publicado: (2020)

BRCA-mutated gastric adenocarcinomas are associated with chromosomal instability and responsiveness to platinum-based chemotherapy
por: Oh, Ji Hyun, et al.
Publicado: (2023)

Glucocorticoid receptor repression mediated by BRCA1 inactivation in ovarian cancer
por: Fang, Yuan-Yuan, et al.
Publicado: (2014)

miR-206 as a prognostic and sensitivity biomarker for platinum chemotherapy in epithelial ovarian cancer
por: Yu, Xiaotang, et al.
Publicado: (2020)

Association of HMGB1, BRCA1 and P62 expression in ovarian cancer and chemotherapy sensitivity
por: Li, Shouyong, et al.
Publicado: (2018)

Ovarian cancer resistance to PARPi and platinum-containing chemotherapy
por: Summey, Rebekah, et al.
Publicado: (2022)

Breast Cancer Epigenetics: From DNA Methylation to microRNAs
por: Veeck, Jürgen, et al.
Publicado: (2010)

Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer NCI Case Control Study
por: Amira, Gamal, et al.
Publicado: (2019)

Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial
por: Penson, Richard T., et al.
Publicado: (2020)

A novel germline BRCA2 mutation in a Chinese patient with prostate cancer sensitive to platinum chemotherapy: a case report
por: Jiang, Lijuan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l67c014unb49paf6kcrvhkknku